Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G ROSENBLUM

Showing results (101-110 of 243) with videos related to

Pageof 25
Sort By:
Journal of Neuro-Oncology|January 1, 1987
Growth inhibitory effect of recombinant alpha and beta interferon on human glioma cellsW K Yung, P A Steck, P J Kelleher, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1990
Modification of methyliminodiacetato-trans-R,R-1,2-diamminocyclohexane platinum(II) pharmacology using a platinum-specific monoclonal antibodyM G Rosenblum, J L Murray, S Stuckey, et al.
Leukemia|March 1, 2012
Treatment of acute lymphoblastic leukemia with an rGel/BLyS fusion toxinR Parameswaran, M Yu, M-A Lyu, et al.
Cancer Immunology, Immunotherapy : CII|February 1, 1996
Cellular resistance to the antimelanoma immunotoxin ZME-gelonin and strategies to target resistant cellsM G Rosenblum, L Cheung, S K Kim, et al.
Gynecologic Oncology Reports|May 17, 2017
Incidental leiomyosarcoma found at the time of cesarean hysterectomy for morbidly adherent placentaLauren C Hand, Alexis C Gimovsky, Joanna S Y Chan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 1999
Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: in vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft modelsM G Rosenblum, L K Shawver, J W Marks, et al.
Cancer Research|November 26, 2009
Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studiesYu Cao, James D Marks, John W Marks, et al.
Oncogene|February 5, 2013
Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studiesY Cao, J W Marks, Z Liu, et al.
Molecular Cancer Therapeutics|March 16, 2013
Construction and characterization of novel, completely human serine protease therapeutics targeting Her2/neuYu Cao, Khalid A Mohamedali, John W Marks, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|February 18, 2014
Photochemical internalization augments tumor vascular cytotoxicity and specificity of VEGF(121)/rGel fusion toxinAnette Weyergang, Lawrence H Cheung, Michael G Rosenblum, et al.
Pageof 25

Showing results (101-110 of 243) with videos related to

Sort By:
Pageof 25
Journal of Neuro-Oncology|January 1, 1987
Growth inhibitory effect of recombinant alpha and beta interferon on human glioma cellsW K Yung, P A Steck, P J Kelleher, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1990
Modification of methyliminodiacetato-trans-R,R-1,2-diamminocyclohexane platinum(II) pharmacology using a platinum-specific monoclonal antibodyM G Rosenblum, J L Murray, S Stuckey, et al.
Leukemia|March 1, 2012
Treatment of acute lymphoblastic leukemia with an rGel/BLyS fusion toxinR Parameswaran, M Yu, M-A Lyu, et al.
Cancer Immunology, Immunotherapy : CII|February 1, 1996
Cellular resistance to the antimelanoma immunotoxin ZME-gelonin and strategies to target resistant cellsM G Rosenblum, L Cheung, S K Kim, et al.
Gynecologic Oncology Reports|May 17, 2017
Incidental leiomyosarcoma found at the time of cesarean hysterectomy for morbidly adherent placentaLauren C Hand, Alexis C Gimovsky, Joanna S Y Chan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 1999
Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: in vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft modelsM G Rosenblum, L K Shawver, J W Marks, et al.
Cancer Research|November 26, 2009
Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studiesYu Cao, James D Marks, John W Marks, et al.
Oncogene|February 5, 2013
Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studiesY Cao, J W Marks, Z Liu, et al.
Molecular Cancer Therapeutics|March 16, 2013
Construction and characterization of novel, completely human serine protease therapeutics targeting Her2/neuYu Cao, Khalid A Mohamedali, John W Marks, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|February 18, 2014
Photochemical internalization augments tumor vascular cytotoxicity and specificity of VEGF(121)/rGel fusion toxinAnette Weyergang, Lawrence H Cheung, Michael G Rosenblum, et al.
Pageof 25